Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPHETIC: Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Ulcerative Colitis
2019-003780-21Phase 4Completed
- Sponsor
- Alimentiv Inc.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Alimentiv Inc. Primary endpoints: Clinical response and remission, Endoscopic response and remission and 3 more. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-003780-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003780-21.